A recently completed phase I trial (NCT00916123) in 15 men with PCa treated in combination with PSMA-targeting antibody [177Lu]Lu-J591 and docetaxel concluded that TRNT could be safely conducted concurrently with standard taxane chemotherapy [235]. This evidence concerns the gene FOLH1 and posterior cortical atrophy.